Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $348,194.00 in Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $24.29 on Friday. The company has a fifty day moving average price of $19.82 and a two-hundred day moving average price of $20.99. Viridian Therapeutics, Inc. has a one year low of $13.18 and a one year high of $34.29. The stock has a market cap of $2.75 billion, a P/E ratio of -7.21 and a beta of 0.91. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The firm had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. As a group, equities analysts predict that Viridian Therapeutics, Inc. will post -4.07 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd acquired a new position in shares of Viridian Therapeutics in the fourth quarter valued at approximately $36,000. KBC Group NV acquired a new stake in Viridian Therapeutics during the 1st quarter worth approximately $34,000. State of Wyoming acquired a new stake in Viridian Therapeutics during the 2nd quarter worth approximately $43,000. Larson Financial Group LLC bought a new stake in Viridian Therapeutics in the 3rd quarter valued at $52,000. Finally, US Bancorp DE boosted its stake in Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares during the period.

Analyst Ratings Changes

A number of brokerages have weighed in on VRDN. Wells Fargo & Company raised Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $20.00 to $31.00 in a research report on Monday, June 29th. Wedbush raised their price objective on Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a research note on Monday, June 29th. Truist Financial boosted their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Royal Bank Of Canada increased their price target on Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.93.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.